{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-004087","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2022-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.213435+00:00","generated_at":"2026-06-26T22:04:37.357436+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta reports full year 2021 net loss of $86.1M; NKX101 data expected 1H 2022","bullets":["Full year 2021 net loss $86.1M ($2.62/share); Q4 net loss $22.8M ($0.69/share).","Cash and investments $240.2M as of Dec 31, 2021; cash runway into 2H 2023.","R&D expenses $63.4M full year; G&A $23.0M; non-cash stock-based comp $14.5M.","NKX101 Phase 1 monotherapy data (AML/MDS) expected 1H 2022; NKX019 data in 2022.","NKX101 received FDA orphan drug designation for AML; protocol amendments filed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-004087","json":"https://secwatch.observer/filing/0000950170-22-004087.json","markdown":"https://secwatch.observer/filing/0000950170-22-004087.md","text":"https://secwatch.observer/filing/0000950170-22-004087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022004087/0000950170-22-004087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017022004087/nktx-20220317.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T22:04:37.357436+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}